From: Cervical cancer risk factors among HIV-infected Nigerian women
 | Univariate | Multivariate | ||
---|---|---|---|---|
 | RR (95%CI) | p-value | RR (95%CI) | p-value |
Socio-demographic characteristics | Â | Â | Â | Â |
Age category (years) | Â | <0.0001* | Â | 0.0005* |
   <30 (ref) | 1.0 |  | 1.0 |  |
   30–34 | 0.8 (0.5–1.1) |  | (0.6–1.3) |  |
   35–39 | 0.6 (0.4–0.9) |  | (0.5–1.1) |  |
   ≥40 | 0.3 (0.2–0.5) |  | 0.4 (0.2–0.7) |  |
Age at first sexual intercourse (years) | Â | 0.06* | Â | 0.05* |
   <15 (ref) | 1.0 |  | 1.0 |  |
   15–19 | 0.9 (0.5–1.6) |  | 0.8 (0.5–1.3) |  |
   20–24 | 0.7 (0.4–1.3) |  | 0.6 (0.4–1.1) |  |
   ≥25 | 0.6 (0.2–1.3) |  | 0.5 (0.2–1.2) |  |
Number of sexual partners | Â | 0.2* | Â | Â |
   ≤2 (ref) | 1.0 |  |  |  |
   3–4 | 1.2 (0.5–2.8) |  |  |  |
   ≥5 | 2.1 (0.7–6.1) |  |  |  |
Total number of pregnancies | Â | 0.03* | Â | 0.1* |
   0–2 (ref) | 1.0 |  | 1.0 |  |
   3–4 | 0.8 (0.5–1.1) |  | 0.7 (0.5–1.1) |  |
   5–6 | 0.6 (0.4–1.0) |  | 0.6 (0.4–1.1) |  |
   ≥7 | 0.7 (0.4–1.1) |  | 0.7 (0.4–1.3) |  |
Total number of abortions | Â | 0.06* | Â | 0.007* |
   0–2 (ref) | 1.0 |  | 1.0 |  |
   3–4 | 1.5 (1.0–2.1) |  | 1.7 (1.1–2.5) |  |
   ≥5 | 1.4 (0.8–2.4) |  | 1.8 (1.0–3.6) |  |
Religion | Â | 0.04 | Â | 0.09 |
   Islam (ref) | 1.0 |  | 1.0 |  |
   Christian | 1.7 (1.0–2.8) |  | 1.5 (0.9–2.5) |  |
Education | Â | 0.5 | Â | Â |
   None (ref) | 1.0 |  |  |  |
   Quaranic | 0.8 (0.1–6.3) |  |  |  |
   Primary | (0.5–2.7) |  |  |  |
   Secondary | (0.7–3.4) |  |  |  |
   Tertiary | 1.3 (0.6–2.8) |  |  |  |
Marital Status | Â | 0.08 | Â | 1.0 |
   Single (ref) | 1.0 |  | 1.0 |  |
   Married | 0.5 (0.4–0.8) |  | (0.6–1.2) |  |
   Widowed | 0.5 (0.3–0.8) |  | (0.6–1.6) |  |
   Divorced | 0.7 (0.4–1.3) |  | (0.6–1.9) |  |
   Cohabiting | 0.6 (0.1–4.1) |  | 0.6 (0.1–4.1) |  |
Occupation | Â | 0.6 | Â | Â |
   Employed (ref) | 1.0 |  |  |  |
   Unemployed | (1.4–4.2) |  |  |  |
   Student | (0.4–5.5) |  |  |  |
   Other | 1.0 (0.5–2.1) |  |  |  |
   N/A | 1.4 (0.4–5.3) |  |  |  |
Contraceptive use | 1.0 (0.7–1.4) | 1.0 |  |  |
Hormonal contraceptives | 0.6 (0.1–3.8) | 0.5 |  |  |
Intrauterine devices | 1.5 (0.5–4.5) | 0.5 |  |  |
Barrier contraceptives | 1.2 (0.8–1.7) | 0.4 |  |  |
Clinical characteristics | Â | Â | Â | Â |
BMI (kg/m2) | Â | 0.8 | Â | Â |
   <18.5 (ref) | 1.0 |  |  |  |
   18.5–24.9 | (0.7–1.5) |  |  |  |
   25–29.9 | 0.6 (0.2–2.5) |  |  |  |
   ≥30 | 1.0 (0.5–1.8) |  |  |  |
Vaginal wall abnormality | Â | 0.0006 | Â | 0.0007 |
   None (ref) | 1.0 |  | 1.0 |  |
   Other | 2.0 (1.3–2.9) |  | 1.9 (1.3–2.8) |  |
Last CD4 count (per mm3) | Â | <0.0001* | Â | <0.0001* |
   <300 (ref) | 1.0 |  | 1.0 |  |
   300–<450 | 0.5 (0.3–0.7) |  | (0.3–0.7) |  |
   450–<650 | 0.5 (0.3–0.7) |  | 0.5 (0.3–0.8) |  |
   ≥650 | 0.3 (0.2–0.5) |  | 0.3 (0.2–0.6) |  |
WHO stage | Â | 1.0 | Â | Â |
   Stage 1 (ref) | 1.0 |  |  |  |
   Stage 2 | (0.2–1.4) |  |  |  |
   Stage 3 | 1.3 (0.6–2.7) |  |  |  |
   Stage 4 | 1.6 (0.2–10.2) |  |  |  |
ART Regimen currently on | Â | 0.6 | Â | Â |
   TDF-containing ART | 1.4(1.0–2.0) |  |  |  |
   ZDV-containing ART | (1.0–2.2) |  |  |  |
   d4T-containing ART | 0.9 (0.4–2.1) |  |  |  |